Table 2.

Comparative efficacy and tolerability of CGRP mAb's with topiramate and onabotulinumtoxinA.

	Epti EM	Epti CM	Eren EM	Eren CM	Frem EM	Frem CM	Gal EM	Gal CM	TPM 50–200 mg EM	OnBTA 16–190.5 u EM	OnBTA 100–190 u CM
50% responder rate odds ratio	1.29 (0.67–2.49) to 2.16 (1.47–3.39	1.80 (1.07–3.03) to 2.09 (1.71–2.38)	1.12 (0.65–1.94) to 5.12 (2.42–10.81)	1.57 (1.12–2.23) to 2.27 (1.52–3.39	2.06 (1.46–2.92) to 3.21 (1.77–5.81)	2.44 (1.32–4.54) to 3.11 (2.23–4.35)	1.55 (0.84–2.83) to 3.38 (1.95–5.95)	2.10 (1.47–2.99) to 4.58 (2.02–10.32)	1.27 (0.70–2.31) to 32.5 (2.79–378.66)	0.78 (0.52–1.18) to 2.56 (0.99–6.63)	1.28 (0.98–1.67) to 2.57 (0.52–12.76)
Overall 50% responder odds ratio	2.33 (2.08–2.60)								2.67 (1.94–3.68)		1.28 (0.98–1.67)
AE %	57.7–59.7	47.8–56.1	48.4–66.8	45.5	50.0–62.4	50.5–70.5	51.0–68.3	51.0–57.5	44.5		57.3
Drop out %	3.5–4.3	1.0–2.0	1.1–3.6	3.5	1.0–9.1	1.0–1.7	2.4–17.8	0.9–2.4	29.0		3.4

Epti, Eptinezumab; Eren, Erenumab; Frem, Fremanezumab; Gal, Galcanezumab; TPM, Topiramate; OnBTA, OnabotulinumtoxinA; EM, Episodic Migraine; CM, Chronic Migaine; AE, Adverse events.